3 articles
Biolojic Design's AI-generated antibody BD200 demonstrated superior efficacy in cancer models resistant to current treatments, while JATT II Acquisition Corp raised $60M through an IPO targeting AI-driven biotechnology companies. The dual developments signal growing capital formation around computational drug design.
Virtual twin-guided medical procedures reached 2,000 cases in March 2026, seven years after FDA joined the Living Heart Project that created the first fully functional virtual heart model. FDA published its first in silico clinical trial guidelines in August 2024, formalizing a regulatory pathway that pharmaceutical and medical device companies are now using to compress development timelines and slash trial costs.
A concentrated wave of regulatory filings and clinical validations across the precision oncology sector signals a potential consolidation opportunity for investors. With multiple FDA submissions planned for Q1-Q2 2026 and compelling clinical data emerging across targeted therapies, antibody-drug conjugates, and combination approaches, the sector is demonstrating both scientific maturity and commercial readiness.